TPBG
FATE icon

Turning Point Benefit Group’s Fate Therapeutics FATE Stock Holding History

Turning Point Benefit Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14
Closed -$13 – 338
2025
Q4 		$13 Hold
14
– – ﹤0.01% 844
2025
Q3 		$17 Buy
+14
New +$15 ﹤0.01% 755

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Turning Point Benefit Group's FATE Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Fate Therapeutics (FATE) in Q1 2026, closing a stake of 14 shares — an estimated $13 sold.

Turning Point Benefit Group first reported a position in FATE in Q3 2025 and held it in 2 quarters. The position peaked at $17 in Q3 2025. 158 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Fate Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 14 Fate Therapeutics shares in Q1 2026, an estimated $13.
  • Turning Point Benefit Group first reported a position in Fate Therapeutics in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Fate Therapeutics position peaked at $17 in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.